HSPE1

10 kDa heat shock protein, mitochondrial · P61604 · HSPE1 on Sugi Atlas →

78,069 patent compounds predicted against HSPE1, 61,481 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
4'-Hydroxychalcone (SCHEMBL127606)	1.00	3/20
Tribromsalan (SCHEMBL121315)	0.79	3/20
Chalcone (SCHEMBL27580)	0.78	3/20
Chalcone (SCHEMBL27581)	0.78	3/20
SCHEMBL67608	0.48	3/20
Cholecalciferol (SCHEMBL3126)	1.00	2/20
Cholecalciferol (SCHEMBL3127)	1.00	2/20
Ergocalciferol (SCHEMBL3420)	1.00	2/20
Ergocalciferol (SCHEMBL3421)	1.00	2/20
Ergocalciferol (SCHEMBL3422)	1.00	2/20
Cholecalciferol (SCHEMBL15694)	1.00	2/20
Cholecalciferol (SCHEMBL15695)	1.00	2/20
Benzethonium (SCHEMBL21713)	1.00	2/20
Menadione (SCHEMBL25970)	1.00	2/20
Plumbagin (SCHEMBL34186)	1.00	2/20
Aurintricarboxylic Acid (SCHEMBL98495)	1.00	2/20
Evans Blue Free Acid (SCHEMBL103701)	1.00	2/20
Closantel (SCHEMBL116617)	1.00	2/20
Benzethonium (SCHEMBL122985)	1.00	2/20
Eprinomectin (SCHEMBL120548)	0.98	2/20

Clinical trials — most relevant to HSPE1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
OGX-427 in Castration Resistant Prostate Cancer Patients	PHASE2	COMPLETED
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease	PHASE2	COMPLETED
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma	PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies	PHASE1	WITHDRAWN
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas	PHASE1	COMPLETED
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)	EARLY_PHASE1	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Perfusion-Induced Hyperthermia for Metastatic Carcinoma	nan	COMPLETED
Trial of Nonsurgical Treatment of Intermittent Claudication Due to Femoro-popliteal Disease	nan	COMPLETED
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide	nan	RECRUITING
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy	nan	COMPLETED
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study)	nan	COMPLETED
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk	nan	COMPLETED
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC	nan	COMPLETED
Mitoquines in COPD	nan	UNKNOWN
Acute Passive Heating in Healthy Older Adults	nan	COMPLETED
Predicting Pancreatic Necrosis Using mitDNA	nan	UNKNOWN
Effects of Acute Energy Deficit and Aerobic Exercise on Muscle Quality	nan	COMPLETED
The Role of HSP90 in Peripheral Vascular Lesions of Diabetic Atherosclerosis	nan	COMPLETED
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.	nan	NOT_YET_RECRUITING
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
Nicotinamide Riboside and Mitochondrial Biogenesis	nan	COMPLETED
Calorie Restriction and Brain Function in Mild Cognitive Impairment	nan	COMPLETED
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise	nan	COMPLETED
Mechanisms Underlying Hypoxic, Heat and Cross-tolerance Adaptation in Women	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a HSPE1 binder may also engage these)

Protein	Name	Similarity
P61603	—	1.000	P61603 →
P26772	—	1.000	P26772 →
Q64433	—	1.000	Q64433 →
Q5DC69	—	0.999	Q5DC69 →
Q9W6X3	—	0.997	Q9W6X3 →
P38910	—	0.995	P38910 →
Q96539	—	0.994	Q96539 →
Q9AMJ9	—	0.993	Q9AMJ9 →
O59804	—	0.993	O59804 →
P34893	—	0.991	P34893 →
Q8KJ17	—	0.990	Q8KJ17 →
Q6LM05	—	0.989	Q6LM05 →
C1C9H7	—	0.989	C1C9H7 →
B0BPV2	—	0.989	B0BPV2 →
B4U080	—	0.989	B4U080 →
Q8CWN9	—	0.989	Q8CWN9 →
Q2GDC5	—	0.989	Q2GDC5 →
Q5E8E7	—	0.988	Q5E8E7 →
Q7TTX2	—	0.988	Q7TTX2 →
Q487R0	—	0.988	Q487R0 →
A7MX55	—	0.988	A7MX55 →
Q87KX3	—	0.988	Q87KX3 →
Q0I285	—	0.988	Q0I285 →
Q8CWL1	—	0.988	Q8CWL1 →
Q87JG7	—	0.988	Q87JG7 →
Q7M7I1	—	0.988	Q7M7I1 →
B7MKU7	—	0.988	B7MKU7 →
A8A7N8	—	0.988	A8A7N8 →
B7MSG3	—	0.988	B7MSG3 →
A6VM39	—	0.988	A6VM39 →